Immunovia Ab · OMXSTO:IMMNOV
Immunovia Ab — Q3 2022 Earnings Presentation
16 slides from Immunovia Ab's earnings presentation, Nov 10, 2022
Slide 1: Interim report Q3 2022
Interim report Q3 2022 10 November Philipp Mathieu – CEO and President Confidential not for distribution
Slide 2: Forward Looking Statements
Forward Looking Statements • IMPORTANT: The following applies to this document, the oral presentation of the information in this document by Immunovia AB (publ) (the “Company”) or any person on behalf of the Company, and any question-and-answer session that follows the oral presentation (collectivel
Slide 3: Agenda
Agenda • Establishing the leader in the early detection of pancreatic cancer • Q3 Operational highlights • Q3 Financial highlights • Commercial update 2021-09-24 Confidential not for distribution 3
Slide 4: Establishing the leader in the early detection of pancreatic cancer
Establishing the leader in the early detection of pancreatic cancer Front-runner in non-invasive early detection Initial US patient population of over 1.8 million in of pancreatic cancer (PDAC) pancreatic cancer Revolutionizing blood-based Incorporated 2007 in Sweden, 2017 in US diagnostics to Comme
Slide 5: Pancreatic is one of the most lethal cancers with limited diagnostic innovation
Pancreatic is one of the most lethal cancers with limited diagnostic innovation US deaths by cancer 2020 5-year survival rates: Lung 138,225 22.8% Colorectum 54,443 65.1% Pancreas 47,638 11.5% Breast 42,617 90.6% Prostate 32,428 96.8% Liver 31,078 20.8% Non-Hodgkin lymphona 20,858 73.8% Brain, centr
Slide 6: Patients are often diagnosed too late when surgery is no longer an option
Patients are often diagnosed too late when surgery is no longer an option 42% <20% Early Dx 80% Late Dx 3% 5-year survival rate 5-year survival rate when diagnosed early when found late (surgical optionality) (metastatic, non-resectable) Treatment methods: Treatment methods: • Chemotherapy • Chemoth
Slide 7: US addressable patient population of over 1.8 million patients
US addressable patient population of over 1.8 million patients 2022 Total Addressable Patient Population Surveillance Markets ~1M patients • Surveillance generally involves annual imaging to detect pancreatic cancer in high-risk individuals: • Individuals with a family history of pancreatic cancer o
Slide 8: Q3 – Operational highlights
Q3 – Operational highlights • CPT PLA Code for the IMMray™ PanCan-d test approved • Effective since 1st October 2022 • IMMray PanCan-d now available in almost all states in the US (49 out of 50 states) • California license obtained • Preliminary payment rate determination from Centers for Medicare &
Slide 9: Immunovia's strategic partnership with Proteomedix
Immunovia's strategic partnership with Proteomedix Partnership leverages the Companies’ complementary R&D capabilities and advances their R&D efforts ✓ Increased R&D productivity and efficiency ✓ More flexible R&D organization ✓ Focus internal resources on commercial build up – further accelerate ro
Slide 10: Q3 – Financial highlights
Q3 – Financial highlights • Net sales of KSEK 358 (377) • Net earnings amounted to MSEK -23 (-36) • US commercial build up continues • Total Operating Expenses at a steady level • Currency exchange effects and capitalization of R/D in 2021 impacting net earnings comparison • Solid cash position of M
Slide 11: Physician experience program
Physician experience program • Select pancreatic high-risk surveillance centers Interim Update • Limited number of no-charge tests • Providers to become comfortable using IMMray • The program has included 23 high risk PanCan-d surveillance centers around the U.S. • Broadly include IMMray™ PanCan-d i
Slide 12: Physicians appreciate the usefulness of the IMMray test
Pioneers program physician survey – Interim results Physicians appreciate the usefulness of the IMMray test How helpful do you find the IMMray PanCan-d test results for managing your high-risk patients? • “Test results have been concordant with EUS/MRCP to date” Somewhat helpful 11% • “I think the r
Slide 13: Patients are very interested in IMMray PanCan-d testing
Pioneers program physician survey – Interim results Patients are very interested in IMMray PanCan-d testing How receptive are patients to being tested with IMMray PanCan-d? 22% Interested Physicians also indicated that patients are very satisfied with IMMray PanCan-d following testing 78% Very inter
Slide 14: Executing reimbursement plan for US insurance coverage
Executing reimbursement plan for US insurance coverage Extensive payer insights obtained (2021) CAP accreditation received (2021) Peer reviewed blinded validation study published (2021) Physician experience program initiated (2022) PLA code approved (2022) Head of Market Access hired (2022) Pricing
Slide 15: Establishing the leader in the early detection of pancreatic cancer
Establishing the leader in the early detection of pancreatic cancer AREA 2022 ACCOMPLISHMENTS OPERATIONAL ✓ Clear strategic focus on pancreatic cancer ✓ Secured CAP accreditation ✓ Hired experienced commercial leader as US CEO ✓ Hired sales team ✓ Entered into R&D alliance with Proteomedix ADOPTION
Slide 16: Q&A
16 Q&A helloir@immunovia.com www.immunovia.com 2021-09-24 Confidential not for distribution 16